In the past seven years BioIntervene has been working to develop “ultra-selective” compounds to target an adenosine receptor associated with pain relief.
Now the San Diego-based biotech has $30 million and a chief scientific officer, Charles Cohen, to guide its lead compound, BIO-205, into human testing for neuropathic pain. The company announced the Series A financing round and CSO hire on Monday.
BioIntervene’s BIO-205 is an A3 adenosine receptor (A3AR) agonist, which means it homes in on and activates the A3 receptor on adenosine.
BioIntervene’s new CSO, Cohen, in a prepared statement, said BIO-205’s preclinical data demonstrated activity in models of… Read more »
UNDERWRITERS AND PARTNERS
